Nita Seibel, MD

Nita Seibel, MDCancer.Net Specialty Editor: Childhood Cancers
Cancer Therapy Evaluation Program (CTEP).
National Cancer Institute, Bethesda, MD

Dr. Nita L. Seibel is an adjunct professor of pediatrics at George Washington University School of Medicine and Public Health and practices at Children’s National Medical Center.

Dr. Seibel received her medical degree from Ohio State University College of Medicine and Public Health in 1981. After completing her residency in pediatrics at Ohio State University/ Columbus Children’s Hospital she completed her fellowship in pediatric hematology/oncology on the Pediatric Oncology Branch of the National Cancer Institute. Prior to joining CTEP, Dr. Seibel was an attending physician at Children’s National Medical Center for 20 years. She held numerous positions there which included Solid Tumor Director, Fellowship Training Program Director for Hematology/Oncology, Outreach Services Director for the Department of Hematology/Oncology, and Principal Investigator for the Children’s Oncology Group as well as Professor of Pediatrics at George Washington University School of Medicine. She is board certified in pediatrics and pediatric hematology/oncology.

Dr. Seibel joined the Clinical Investigations Branch of CTEP in 2008 to oversee the development of the Pediatric Solid Tumor extramural program, long term childhood cancer survivorship, Pediatric Central Institutional Review Board and adolescent and young adult cancer program. She is a member of the NCI PDQ (Physician Data Query) Pediatric Board and previously was the American Society Pediatric Hematology-Oncology representative to the Alliance for Childhood Cancer. She has chaired numerous studies in the Children’s Cancer Group (CCG), was a member of the CCG Bone Tumor Strategy Committee and the National Wilms Tumor Study Group prior to the merger into the COG. She was a member of the COG Renal Tumor Group, chaired the Higher Risk Favorable Histology Wilms’ Tumor study and the COG Phase I Data and Safety Monitoring Committee prior to joining CTEP.

Dr. Seibel has a long interest in new agents both for oncology and fungal infections and collaborated on numerous studies in these areas. She served as vice chair for Phase I agents for the CCG and has a special interest in Acute Lymphoblastic Leukemia (ALL) which was manifested in chairing the CCG 1961 Treatment of Higher Risk Acute Lymphoblastic Leukemia protocol. She is a regular reviewer for numerous journals including CancerJournal of Pediatric Hematology/OncologyPediatric Blood and CancerJournal of Clinical Oncology, and Clinical Infectious Disease. Dr. Seibel has spoken internationally on the treatment and management of invasive mycoses and ALL in children and adolescents. She has chaired and participated in sessions at ASCO, American Society of Hematology, and the American Society of Pediatric Hematology/Oncology national meetings. She has served on the ASCO Integrated Media and Technology Committee, the planning committee for the AYA CME module and speaker for the ASCO-Livestrong Focus Under Forty module and search committees for the ASCO Education Book Editor and ASCO University Editor.

She is currently the co-chair of the NCI-Children’s Oncology Group Pediatric Molecular Analysis for Therapy Choice (MATCH) study; scientific liaison of the Childhood Cancer Survivor Study (CCSS) and New Approaches in Neuroblastoma Treatment (NANT) and NCI Pediatric Central Institutional Review Board, co-chair of the trans-NCI Adolescent and Young Adult Working Group, and member of the NCI Physician Data Query (PDQ) Pediatric Board.

Dr. Seibel has been named in multiple consecutive surveys by the Washingtonian as a Top Doctor. In addition to her many invited lectures; Dr. Seibel has published over 100 articles, multiple abstracts, and numerous book chapters. In addition to her interest in new oncology agents, antifungal agents, Wilms’ tumors, and ALL, she also is interested in adolescent and young adult oncology, clear cell sarcoma of the kidney, osteosarcoma and Ewing sarcoma.

View current ASCO disclosure here

Last updated: September 2018